Data gathered: November 27
Alternative Data for Tscan Therapeutics
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Sentiment | 100 | Sign up | Sign up | Sign up |
| Webpage traffic | 4,000 | Sign up | Sign up | Sign up |
| Google Trends | N/A | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 1 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 634 | Sign up | Sign up | Sign up |
| Twitter Mentions | 6 | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
About Tscan Therapeutics
None
| Price | $4.77 |
| Target Price | Sign up |
| Volume | 99,290 |
| Market Cap | $241M |
| Year Range | $3.94 - $9.51 |
| Dividend Yield | 0% |
| Analyst Rating | 100% buy |
| Industry | Biotechnology |
In the news
 |
Lifesci Capital Has Pessimistic View of TCRX FY2024 EarningsNovember 16 - ETF Daily News |
|
Research Analysts Set Expectations for TCRX FY2028 EarningsNovember 15 - ETF Daily News |
 |
TScan Therapeutics, Inc. (TCRX) Reports Q3 Loss, Misses Revenue EstimatesNovember 11 - Yahoo |
|
TScan Therapeutics’ (TCRX) “Buy” Rating Reiterated at Needham & Company LLCNovember 8 - ETF Daily News |
 |
TScan Therapeutics (TCRX) Soars 7.6%: Is Further Upside Left in the Stock?November 6 - Yahoo |
TScan Therapeutics (TCRX) Gets a Buy from BarclaysOctober 29 - TipRanks |
|
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q3 '24 | 49,000 | 7.4M | -7.4M | -30M | 0 | -0.250 |
| Q2 '24 | 540,000 | 7.8M | -8.2M | -32M | -34M | -0.280 |
| Q1 '24 | 570,000 | 7.1M | -7.5M | -30M | -31M | -0.320 |
| Q4 '23 | 6.4M | 12M | -5.2M | -20M | -20M | -0.210 |
| Q3 '23 | 2.9M | 5.9M | -3M | -23M | -25M | -0.240 |
Insider Transactions View All
| Klencke Barbara filed to buy 45,000 shares at $5.3. September 24 '24 |
| Klencke Barbara filed to buy 40,000 shares at $5.5. August 27 '24 |
| ZDRAVESKI ZORAN filed to sell 4,716 shares at $5.8. August 27 '24 |
| BAKER JULIAN filed to buy 4,018,678 shares at $7.1. April 23 '24 |
| Nichols Weston filed to buy 5,000,000 shares at $7.1. April 23 '24 |
Similar companies
Read more about Tscan Therapeutics (TCRX) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, sentiment, webpage traffic, google trends, 4chan mentions, reddit mentions, stocktwits mentions, stocktwits subscribers, twitter mentions, news mentions & customer reviews.
What is the Market Cap of Tscan Therapeutics?
The Market Cap of Tscan Therapeutics is $241M.
What is the current stock price of Tscan Therapeutics?
Currently, the price of one share of Tscan Therapeutics stock is $4.77.
How can I analyze the TCRX stock price chart for investment decisions?
The TCRX stock price chart above provides a comprehensive visual representation of Tscan Therapeutics' stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Tscan Therapeutics shares. Our platform offers an up-to-date TCRX stock price chart, along with technical data analysis and alternative data insights.
Does TCRX offer dividends to its shareholders?
As of our latest update, Tscan Therapeutics (TCRX) does not offer dividends to its shareholders. Investors interested in Tscan Therapeutics should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
What are some of the similar stocks of Tscan Therapeutics?
Some of the similar stocks of Tscan Therapeutics are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
.